Federated Hermes
TYRA icon

Federated Hermes’s Tyra Biosciences TYRA Stock Holding History

Federated Hermes’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.3K Sell
714
-583
-45% -$18.9K ﹤0.01% 1748
2025
Q4 		$34.1K Sell
1,297
-858
-40% -$15.8K ﹤0.01% 1681
2025
Q3 		$30.1K Buy
2,155
+1,841
+586% +$21K ﹤0.01% 1756
2025
Q2 		$3K Sell
314
-161
-34% -$1.53K ﹤0.01% 1928
2025
Q1 		$4.42K Sell
475
-553
-54% -$7.16K ﹤0.01% 1889
2024
Q4 		$14.3K Buy
1,028
+98
+11% +$1.78K ﹤0.01% 1803
2024
Q3 		$21.9K Buy
930
+364
+64% +$7.64K ﹤0.01% 1744
2024
Q2 		$9.05K Sell
566
-147
-21% -$2.53K ﹤0.01% 1790
2024
Q1 		$11.7K Sell
713
-1,357
-66% -$22.3K ﹤0.01% 1763
2023
Q4 		$28.7K Buy
2,070
+1,916
+1,244% +$24.8K ﹤0.01% 1711
2023
Q3 		$2.12K Sell
154
-2,911
-95% -$43.2K ﹤0.01% 1966
2023
Q2 		$52.2K Buy
3,065
+3,011
+5,576% +$43.7K ﹤0.01% 1664
2023
Q1 		$868 Buy
+54
New +$642 ﹤0.01% 2049

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Federated Hermes's TYRA Position: Q1 2026 in Review

Federated Hermes reduced its Tyra Biosciences (TYRA) stake by 45% in Q1 2026, selling an estimated $18.9K and leaving 714 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Federated Hermes first reported a position in TYRA in Q1 2023 and has held it in 13 quarters since. The position peaked at $52.2K in Q2 2023. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Federated Hermes held 714 shares of Tyra Biosciences worth $27.3K as of Q1 2026.
  • Federated Hermes sold 583 Tyra Biosciences shares in Q1 2026, an estimated $18.9K.
  • Tyra Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1748 holding.
  • Federated Hermes first reported a position in Tyra Biosciences in Q1 2023 and has held it in 13 quarters since.
  • Federated Hermes's Tyra Biosciences position peaked at $52.2K in Q2 2023.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.